title: Sirt1 inhibits resistin expression in aortic stenosis.
abstract: The development of human calcified aortic stenosis (AS) includes age-dependent processes that have been involved in atherosclerosis, such as infiltration of macrophages in aortic valves, which then promote production of many pro-inflammatory cytokines, including resistin. However, the molecular mechanisms contributing to these processes are not established. Since Sirt1 has been shown to modulate macrophage biology and inflammation, we examined its levels in human AS and tested its impact on resistin expression. Sirt1 mRNA (p = 0.01) and protein (p<0.05) levels were reduced in explanted valves from AS patients (n = 51) compared to those from control (n = 11) patients. Sirt1 mRNA levels were negatively associated with resistin mRNA levels quantified in AS valves (p = 0.02). Stimulation of Sirt1 by resveratrol or virus-driven overexpression robustly diminished resistin mRNA and protein expression in macrophages, whereas down-regulation of Sirt1 triggered a large increase in resistin expression. These effects were direct, as chromatin immunoprecipitation assays showed that Sirt1 physically interacted with the resistin promoter region at an AP-1 response element. Moreover, Sirt1 blocked c-jun-induced resistin transactivation in gene reporter assays. These findings demonstrate that, in calcified AS, levels of Sirt1 are reduced whereas those of resistin are increased within aortic valve leaflets. Our results also suggest that this loss of Sirt1 expression alleviates its inhibition of resistin transcription in macrophages. Although the overall contribution of this process to the underlying mechanisms for AS disease development remains unresolved, these observations suggest that modification of Sirt1 expression and/or activity could represent a novel approach against inflammation in AS.
authors.affiliation: Quebec Heart and Lung Research Center, Laval University, Québec, Québec City, Canada.
authors.forename: Sophie
authors.initials: S
authors.lastname: Carter
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Miard
authors.forename: Catherine
authors.initials: C
authors.lastname: Roy-Bellavance
authors.forename: Louise
authors.initials: L
authors.lastname: Boivin
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Li
authors.forename: Philippe
authors.initials: P
authors.lastname: Pibarot
authors.forename: Patrick
authors.initials: P
authors.lastname: Mathieu
authors.forename: Frédéric
authors.initials: F
authors.lastname: Picard
mesh_terms: D000368:Aged; D000818:Animals; D001021:Aortic Valve / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D001024:Aortic Valve Stenosis / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D001665:Binding Sites; D002478:Cells, Cultured; D047369:Chromatin Immunoprecipitation; D005786:Gene Expression Regulation / Q000187:drug effects; D017930:Genes, Reporter; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008875:Middle Aged; D011485:Protein Binding; D012333:RNA, Messenger / Q000096:biosynthesis; D052243:Resistin / Q000235:genetics* / Q000378:metabolism; D020218:Response Elements; D000077185:Resveratrol; D056564:Sirtuin 1 / Q000235:genetics* / Q000378:metabolism; D013267:Stilbenes / Q000494:pharmacology; D014158:Transcription, Genetic
chemical_list: D008070:Lipopolysaccharides; D012333:RNA, Messenger; D052243:Resistin; D013267:Stilbenes; D048031:JNK Mitogen-Activated Protein Kinases; D056564:Sirtuin 1; D000077185:Resveratrol